QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
NYSE:AMRX

Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

$2.22
-0.01 (-0.45%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.17
▼
$2.29
50-Day Range
$2.02
▼
$2.71
52-Week Range
$2.00
▼
$5.99
Volume
549,170 shs
Average Volume
827,765 shs
Market Capitalization
$673.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.7% Upside
$5.50 Price Target
Short Interest
Bearish
4.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
0.81mentions of Amneal Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.54%
From $0.65 to $0.79 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

77th out of 1,075 stocks

Pharmaceutical Preparations Industry

25th out of 537 stocks

See Top Rated MarketRank™ Stocks Here
AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Stock News Headlines

October 6, 2022 | finance.yahoo.com
Amneal to Report Third Quarter 2022 Results on November 4, 2022
October 4, 2022 | fool.com
Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
October 3, 2022 | finance.yahoo.com
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
September 20, 2022 | nasdaq.com
With 42% stake, Amneal Pharmaceuticals, Inc. (NYSE:AMRX) seems to have captured institutional investors' interest
September 17, 2022 | seekingalpha.com
AMRX Amneal Pharmaceuticals, Inc.
September 16, 2022 | finance.yahoo.com
10 Best 52-Week Low Small-Cap Stocks to Buy Now
September 13, 2022 | morningstar.com
Amneal Pharmaceuticals Inc Ordinary Shares - Class A
September 6, 2022 | finance.yahoo.com
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
September 1, 2022 | finance.yahoo.com
Amneal Seeks FDA Approval For Its Parkinson's Candidate
August 31, 2022 | finance.yahoo.com
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
August 22, 2022 | finance.yahoo.com
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
August 11, 2022 | finance.yahoo.com
Amneal launches 4 new Generic products, including Vasopressin single-dose
August 8, 2022 | finance.yahoo.com
Insiders who placed huge bets on Amneal Pharmaceuticals, Inc. (NYSE:AMRX) earlier this year would be disappointed with the 10% drop
August 7, 2022 | nasdaq.com
Does Amneal Pharmaceuticals (NYSE:AMRX) Have A Healthy Balance Sheet?
August 5, 2022 | seekingalpha.com
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results - Earnings Call Transcript
August 5, 2022 | seekingalpha.com
Amneal shares lower after generic drugmaker cuts FY 2022 profit outlook
August 5, 2022 | finance.yahoo.com
Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022
August 5, 2022 | finance.yahoo.com
Amneal Reports Second Quarter 2022 Financial Results
August 5, 2022 | finance.yahoo.com
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
July 12, 2022 | finance.yahoo.com
Amneal Pharmaceuticals (NYSE:AMRX) shareholders have endured a 31% loss from investing in the stock a year ago
July 8, 2022 | finance.yahoo.com
Amneal to Report Second Quarter 2022 Results on August 5, 2022
July 1, 2022 | seekingalpha.com
Endo adds over 27% after favorable trial verdict
June 7, 2022 | finance.yahoo.com
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
June 1, 2022 | seekingalpha.com
Amneal launches Lyvispah for muscle tightness due to spinal cord & neurological disorders
June 1, 2022 | finance.yahoo.com
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Company Calendar

Last Earnings
8/05/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AMRX
CUSIP
N/A
CIK
1723128
Web
www.amneal.com
Phone
(908) 947-3120
Fax
908-947-3146
Employees
7,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+147.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
3.42
P/E Growth
0.14
Net Income
$10.62 million
Net Margins
-6.29%
Pretax Margin
-12.30%
Return on Equity
56.26%
Return on Assets
4.72%

Debt

Debt-to-Equity Ratio
15.38
Current Ratio
1.56
Quick Ratio
1.03

Sales & Book Value

Annual Sales
$2.09 billion
Price / Sales
0.32
Cash Flow
$1.56 per share
Price / Cash Flow
1.42
Book Value
$1.22 per share
Price / Book
1.82

Miscellaneous

Outstanding Shares
303,525,000
Free Float
222,241,000
Market Cap
$673.83 million
Optionable
Optionable
Beta
1.29

Key Executives

  • Mr. Chirag K. PatelMr. Chirag K. Patel (Age 55)
    Co-Founder, Co-CEO, Pres & Director
    Comp: $1.52M
  • Mr. Chintu Patel R.Ph (Age 50)
    R.Ph., Co-Founder, Co-CEO & Director
    Comp: $1.53M
  • Mr. Anastasios G. Konidaris (Age 55)
    Exec. VP & CFO
    Comp: $893.24k
  • Ms. Nikita ShahMs. Nikita Shah (Age 44)
    Exec. VP and Chief HR & Strategic Planning Officer
    Comp: $807.09k
  • Mr. Andrew S. Boyer (Age 56)
    Exec. VP & Chief Commercial Officer of Generics
    Comp: $1.1M
  • Mr. Anthony DiMeo
    Sr. Director of Investor Relations
  • Mr. Jason B. Daly Esq. (Age 48)
    Sr. VP, Chief Legal Officer & Corp. Sec.
  • Mr. Sanjiv Patel
    Sr. VP of Operations
  • Dr. Nikunj Patel
    Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
  • Mr. Sanjay Kumar Jain Ph.D.
    Pres of India Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2022?

1 Wall Street analysts have issued twelve-month target prices for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 147.7% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2022?

Amneal Pharmaceuticals' stock was trading at $4.79 on January 1st, 2022. Since then, AMRX shares have decreased by 53.7% and is now trading at $2.22.
View the best growth stocks for 2022 here.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 4,600,000 shares, an increase of 15.3% from the August 31st total of 3,990,000 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is presently 4.3 days. Currently, 4.7% of the company's stock are sold short.
View Amneal Pharmaceuticals' Short Interest.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AMRX earnings forecast.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its quarterly earnings data on Friday, August, 5th. The company reported $0.15 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by $0.03. The firm earned $559.40 million during the quarter, compared to analyst estimates of $534.44 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 56.26% and a negative net margin of 6.29%. Amneal Pharmaceuticals's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.23 EPS.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share guidance of $0.65-$0.70 for the period, compared to the consensus estimate of $0.81. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate of $2.17 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $2.22.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $673.83 million and generates $2.09 billion in revenue each year. The company earns $10.62 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,000 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.